Study on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and serum concentrations of fatty acids

Study on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and serum concentrations of fatty acids - Study on the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and serum concentrations of fatty acids

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060038

Enrollment

Registered

2026-01-01

Start date

2025-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic dysfunction-associated steatotic liver disease (MASLD)

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: MASLD was diagnosed as patients with hepatic steatosis identified by imaging, and any of 1) to 3) 1) Overweight or Obesity 2) type 2 diabetes 3) at least, two metabolic diseases; hypertention, visceral fat accumulation, glucose intolerance, and dyslipidemia

Exclusion criteria

Exclusion criteria: while undergoing cancer therapy CT scan within 1 year

Design outcomes

Primary

Measure	Time frame
Liver/spleen (LS) ratio with abdominal plain CT scan and serum concentrations of fatty acids are measured twice at 12 to 18 month intervals. LS ratio reflects fat accumulation in liver. We examine correlations between change of LS ratio and change of fatty acids.	—

Countries

Japan

Contacts

Public ContactSHIGERU YATOH

Toride-Kitasoma Medical Association Hospital Internal Medicine

shigeru.yatoh@md.tsukuba.ac.jp0297-78-6111

Outcome results